BioLineRx Ltd.
↗Modiin, Israel
BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and rare diseases. The company identifies, in-licenses, and develops promising therapeutic candidates, leveraging its expertise to advance them through clinical development and regulatory processes. Its business model combines proprietary clinical development with strategic partnerships and collaborations with academic and clinical institutions.
The company's pipeline includes motixafortide (APHEXDA®), which is FDA-approved for stem cell mobilization in multiple myeloma, and GLIX1, a first-in-class small molecule targeting DNA damage response currently in Phase 1/2a trials for glioblastoma. BioLineRx operates as a foreign private issuer, with shares traded on NASDAQ and the Tel Aviv Stock Exchange.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$1M-$2M
Founded:2003
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$34.5M (noted as private placement)
Investors:Novartis (historical stake)
STOCK
Exchange:NASDAQ
Ticker:BLRX
Market Cap:$0.01B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Motixafortide)
Modalities:Small molecule, Peptide
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Biokine
Key Partnerships:Ayrmid Ltd. (Commercialization of APHEXDA), Gloria Biosciences (Development/Commercialization of APHEXDA in Asia), Columbia University (PDAC trial), Hemispherian AS (GLIX1 collaboration)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Philip A. Serlin - CEO
Mali Zeevi - CFO
Board Members:Aharon Schwartz, BJ Bormann, Gal Cohen, Rami Dar, Rafael Hofstein, Avraham Molcho, Sandra Panem, Shaoyu Yan
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BioLineRx Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BioLineRx Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.